These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26354986)

  • 1. Is normosmic Parkinson disease a unique clinical phenotype?
    Lee DH; Oh JS; Ham JH; Lee JJ; Lee I; Lee PH; Kim JS; Sohn YH
    Neurology; 2015 Oct; 85(15):1270-5. PubMed ID: 26354986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.
    Jennings D; Siderowf A; Stern M; Seibyl J; Eberly S; Oakes D; Marek K;
    JAMA Neurol; 2017 Aug; 74(8):933-940. PubMed ID: 28595287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease.
    Ponsen MM; Stoffers D; Wolters ECh; Booij J; Berendse HW
    J Neurol Neurosurg Psychiatry; 2010 Apr; 81(4):396-9. PubMed ID: 19965851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.
    Jennings D; Siderowf A; Stern M; Seibyl J; Eberly S; Oakes D; Marek K;
    Neurology; 2014 Nov; 83(19):1739-46. PubMed ID: 25298306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor features in Parkinson's disease with normal olfactory function.
    Rossi M; Escobar AM; Bril A; Millar Vernetti P; De Palo JI; Cerquetti D; Merello M
    Mov Disord; 2016 Sep; 31(9):1414-7. PubMed ID: 27277396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.
    Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS
    J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal Dopamine Transporter Modulation After Rotigotine: Results From a Pilot Single-Photon Emission Computed Tomography Study in a Group of Early Stage Parkinson Disease Patients.
    Rossi C; Genovesi D; Marzullo P; Giorgetti A; Filidei E; Corsini GU; Bonuccelli U; Ceravolo R
    Clin Neuropharmacol; 2017; 40(1):34-36. PubMed ID: 27941527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease.
    Hong JY; Oh JS; Lee I; Sunwoo MK; Ham JH; Lee JE; Sohn YH; Kim JS; Lee PH
    Neurology; 2014 May; 82(18):1597-604. PubMed ID: 24719485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor and non-motor correlates of olfactory dysfunction in Parkinson's disease.
    Berendse HW; Roos DS; Raijmakers P; Doty RL
    J Neurol Sci; 2011 Nov; 310(1-2):21-4. PubMed ID: 21705022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients.
    Santangelo G; Vitale C; Picillo M; Cuoco S; Moccia M; Pezzella D; Erro R; Longo K; Vicidomini C; Pellecchia MT; Amboni M; Brunetti A; Salvatore M; Barone P; Pappatà S
    Parkinsonism Relat Disord; 2015 May; 21(5):489-93. PubMed ID: 25753457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of RNA Blood Biomarkers in Individuals at Risk of Parkinson's Disease.
    Santiago JA; Potashkin JA
    J Parkinsons Dis; 2017; 7(4):653-660. PubMed ID: 28922168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olfactory Dysfunction Predicts Disease Progression in Parkinson's Disease: A Longitudinal Study.
    He R; Zhao Y; He Y; Zhou Y; Yang J; Zhou X; Zhu L; Zhou X; Liu Z; Xu Q; Sun Q; Tan J; Yan X; Tang B; Guo J
    Front Neurosci; 2020; 14():569777. PubMed ID: 33381006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idiopathic hyposmia as a preclinical sign of Parkinson's disease.
    Ponsen MM; Stoffers D; Booij J; van Eck-Smit BL; Wolters ECh; Berendse HW
    Ann Neurol; 2004 Aug; 56(2):173-81. PubMed ID: 15293269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients.
    Erro R; Pappatà S; Amboni M; Vicidomini C; Longo K; Santangelo G; Picillo M; Vitale C; Moccia M; Giordano F; Brunetti A; Pellecchia MT; Salvatore M; Barone P
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1034-8. PubMed ID: 22789824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal Dopamine Depletion Patterns and Early Non-Motor Burden in Parkinsons Disease.
    Chung SJ; Lee JJ; Ham JH; Ye BS; Lee PH; Sohn YH
    PLoS One; 2016; 11(8):e0161316. PubMed ID: 27529171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between cerebral vascular disease and parkinsonism: The VADO study.
    Antonini A; Vitale C; Barone P; Cilia R; Righini A; Bonuccelli U; Abbruzzese G; Ramat S; Petrone A; Quatrale R; Marconi R; Ceravolo R; Stefani A; Lopiano L; Zappia M; Capus L; Morgante L; Tamma F; Tinazzi M; Colosimo C; Guerra UP
    Parkinsonism Relat Disord; 2012 Jul; 18(6):775-80. PubMed ID: 22531611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Dominant-Side Onset Associated With a Better Motor Compensation in Parkinson's Disease?
    Ham JH; Lee JJ; Kim JS; Lee PH; Sohn YH
    Mov Disord; 2015 Dec; 30(14):1921-5. PubMed ID: 26408124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study.
    Ikeda K; Yanagihashi M; Miura K; Ishikawa Y; Hirayama T; Takazawa T; Kano O; Kawabe K; Mizumura N; Iwasaki Y
    J Neurol Sci; 2018 Aug; 391():5-9. PubMed ID: 30103971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does smoking impact dopamine neuronal loss in de novo Parkinson disease?
    Lee Y; Oh JS; Chung SJ; Chung SJ; Kim SJ; Nam CM; Lee PH; Kim JS; Sohn YH
    Ann Neurol; 2017 Nov; 82(5):850-854. PubMed ID: 29059491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease.
    Storch A; Wolz M; Beuthien-Baumann B; Löhle M; Herting B; Schwanebeck U; Oehme L; van den Hoff J; Perick M; Grählert X; Kotzerke J; Reichmann H
    Neurology; 2013 May; 80(19):1754-61. PubMed ID: 23576623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.